VTCN1 and triple-negative breast carcinoma: Kinneer et al, developed AZD8205, a B7-H4-directed ADC, and preliminary data indicate that its combination with PARPi can sensitize triple negative breast cancer(TNBC) PDX tumors expressing low levels of B7-H4 (39).